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 themselves be  alerting  features. The guidance should 
not be used as a definitive diagnostic tool to prove or 
disprove maltreatment. This article summarises key 
points in the NICE guidance.
Key points
NICE recommendations are based on systematic 
reviews of best available evidence. When minimal 
evidence is available, recommendations are based on 
the Guideline Development Group’s experience and 
opinion of what constitutes good practice. For this 
guidance, the  Guideline Development Group used 
a formal Delphi consensus process when the group 
did not reach a congruent opinion.  
Alerting features
The guideline recommendations refer to “alerting 
features” in the following categories.
Physical features
Physical features include any serious or unusual 
injury with an absent or unsuitable explanation, and 
particularly in the following categories: abrasions, 
bites, bruises, burns, cold injuries, cuts, lacerations, 
ligature marks, petechiae, scalds, scars, and strangu-
lation marks. They also include various sites of inter-
nal injury including fractures, spinal and intracranial 
injuries (including subdural haemorrhage), intra-
abdominal and intrathoracic injuries, eye injuries 
(including retinal haemorrhage), and oral injuries. 
The recommendations describe specific attributes of 
these injuries and of the child that should lead the 
healthcare professional to consider or suspect child 
maltreatment; in so doing, the recommendations 
draw attention to the age and developmental stage 
of the child and the suitability of the explanation 
given by the parents or carers. 
Sexual abuse
Several recommendations concern alerting features 
that may indicate possible sexual abuse, with par-
ticular attention to the child’s age and sexual devel-
opment. These features include anogenital injuries, 
symptoms, and signs; sexually transmitted infections, 
pregnancy; and sexualised behaviours.
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Why read this summary?
Maltreatment of children is common, with 538 500 
reported referrals to social services departments in 
England1 and 43 411 in Wales2 in the year ending 31 
March 2008, although these probably underestimate 
the true scale of the problem. Child maltreatment 
includes neglect; physical, sexual, and emotional 
abuse; and fabricated or induced illness. It may 
present in various ways to different healthcare pro-
fessionals, who have a “duty . . . to be proactive in 
safeguarding children”3 but often find it difficult to 
act on what they find.
Child maltreatment has short and long term harm-
ful effects on a child’s health and wellbeing; emo-
tional, interpersonal development; and behaviour; 
and in extreme circumstances it may lead to death. 
Children may present with both physical and psy-
chological symptoms and signs that constitute alert-
ing features of one or more types of maltreatment, 
which may also be observed as part of the interac-
tion between the parent or carer and the child.4 The 
effects of maltreatment may continue throughout 
adulthood and include physical disability or disfig-
urement as well as the profound psychological con-
sequences of anxiety, depression, substance misuse, 
and self destructive or antisocial behaviours, which 
may lead to difficulties in forming or sustaining close 
relationships, sustaining employment, and parenting 
capacity.3
Child maltreatment is under-recognised and 
inconsistently reported to children’s social care by 
healthcare professionals in England and Wales.5 The 
recent death of Baby Peter is yet another reminder 
of the consequences of missing the alerting features 
of child maltreatment.6 The recently published 
guidance from the National Institute for Health 
and Clinical Excellence (NICE) aims to raise the 
awareness of healthcare professionals to the alerting 
features of child maltreatment.7 It also aims to sup-
port healthcare professionals who are not special-
ists in child protection in identifying children who 
may be being maltreated and who require further 
multiagency assessment8 to confirm or exclude child 
abuse or neglect. The scope of this guidance does not 
cover family and social risk factors, which may in 
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Clinical presentations
Clinical presentations include (a) unusual patterns 
of use of medical services and attendance at medi-
cal services; (b) discrepant clinical picture (includ-
ing fabricated or induced illness); (c) poor school 
attendance attributed to ill health; as well as (d) 
some particular indicators of ill health (apparent 
life threatening event; hypernatraemia; ingestion of 
substances including poisoning; nasal bleeding; and 
near drowning). 
Neglect
Neglect includes abandonment and several aspects of 
failure of provision and failure of supervision. Many 
of these features must be persistent for a healthcare 
professional to consider or suspect neglect. Aspects 
of neglect through failure of provision may include 
a child who persistently presents as dirty or smelly, 
with unsuitable clothing, severe infestations, with 
untreated tooth decay (when NHS treatment is 
available); whose home conditions are unhygienic 
or unsafe; or who receives inadequate provision of 
food or medication. Other aspects of neglect through 
failure of provision may include lack of adherence 
to necessary medical advice and persistent failure 
to engage with relevant child health promotion pro-
grammes, such as immunisation, health and develop-
ment reviews, and screening. Failure of supervision 
may be indicated by injuries—for example, a burn, 
sunburn, an ingestion of a harmful substance, or an 
animal bite.
The child’s emotional, behavioural, and interpersonal 
functioning
This section includes a child’s particular behaviours, 
emotional states, patterns of interpersonal  functioning, 
When to suspect maltreatment of a child
CONSIDER means maltreatment is one possible explanation for
the alerting feature or is included in the differential diagnosis
CONSIDER child maltreatment
If an alerting feature prompts you to consider child maltreatment:
• Look for other alerting features of maltreatment in the child or
   young person’s history, presentation, or interactions between
   the child and parent or carer now or in the past
And do one or more of the following:
• Discuss the case with a more experienced colleague, a
   community paediatrician, child and adolescent mental health
   service colleague, or a named or designated professional for
   safeguarding children
• Gather collateral information from other agencies and health
   disciplines
• Ensure review of the child or young person at a date appropriate
   to the concern, looking out for repeated presentations of this or
   any other alerting features
At any stage during the process of considering maltreatment the
level of concern may change and lead to excluding or suspecting
maltreatment
Listen and observe
Take into account the whole picture of the child or young person. Sources of information that help to do this include:
• Any history that is given
• Report of maltreatment, or disclosure from a child or young
   person or third party
• Child’s appearance, demeanour, or behaviour
Record
Record in the child or young person’s clinical record exactly what is observed and heard from whom and when
Record why this is of concern
• Symptom
• Physical sign
• Result of an investigation
• Interaction between the parent or carer and child or young person
Seek an explanation
Seek an explanation for any injury or presentation from both the parent or carer and the child or young person in an open and
  non-judgmental manner
An unsuitable explanation is one that is:
• Implausible, inadequate or inconsistent:
• Based on cultural practice, because this should not justify hurting a child or young person
- With the child or young person’s presentation, normal activities, medical condition (if one
   exists), age or developmental stage, or account compared with that given by parent and carers
- Between parents or carers
- Between accounts over time
SUSPECT means serious level of concern exists about the
possibility of child maltreatment but not proof of it
Record
Record all actions taken and the outcome
SUSPECT child maltreatment
If an alerting feature or
considering child maltreatment
prompts you to suspect child
maltreatment refer the child or
young person to children’s
social care, following Local
Safeguarding Children Board
procedures
Exclude child maltreatment
Exclude child maltreatment if a
suitable explanation is found
for the alerting feature
This may be the decision after
discussion of the case with a
more experienced colleague or
gathering collateral information
as part of considering child
maltreatment
The alerting features in this guidance have been divided into two categories, according to the level of concern, with recommendations
either to “consider” or to “suspect” maltreatment
If you encounter an "alerting feature" (as described in the guidance) it is good practice to follow the process outlined below
Chart amended with permission from NICE6
Definitions
Using the guidance
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and other aspects of the child’s functioning. These 
behaviours comprise a wide range of features includ-
ing aggression; fearfulness; dissociation; low self 
esteem; indiscriminate contact or affection seeking; 
self harm; running away from home; body rocking; 
aspects of eating and feeding; and soiling and wetting 
behaviour. Patterns of potential concern include age 
inappropriate behaviour; marked change in emotional 
or behavioural state; and repeated, extreme, or sus-
tained emotional responses by a child that are out of 
proportion to a situation and are not expected for his 
or her age and developmental stage.
Interactions between parent and child
Several aspects of interactions between a child and 
the parent or carer may be harmful, especially when 
persistent. They include emotional unavailability 
and unresponsiveness from the parent or carer; 
hostility towards and rejection and scapegoating 
of a child; interactions and expectations that are 
inappropriate for the age of the child, including 
inappropriate threats or methods of disciplining; 
exposure to domestic abuse; using the child to fulfil 
the parent’s or carer’s needs (for example, involving 
the child in marital disputes); and failing to pro-
mote the child’s socialisation by isolation or lack of 
stimulation or education, or by involving the child 
in unlawful activities.
Terminology
The terms “consider” and “suspect” have been used 
in the guidance to indicate the level of concern with 
respect to the various alerting features. These two 
terms reflect the action(s) to be taken by the health-
care professional when encountering the particu-
lar alerting feature (figure). The associated actions 
are intended to direct healthcare professionals to 
resources or ways of thinking that will enable them 
to overcome barriers to recognising maltreatment. 
“Consider” means that maltreatment is one possible 
explanation for the alerting feature or is included in 
the differential diagnosis.
The actions recommended in the figure will lead 
the healthcare professional to exclude maltreatment, 
to continue to keep the case under consideration, 
or to move to a stage of heightened concern where 
they suspect maltreatment.
“Suspect” means a serious level of concern about 
the possibility of maltreatment but is not proof of 
it. This may trigger a child protection investigation, 
which may indicate the need for starting child protec-
tion procedures and/or offering supportive services to 
the family or may lead to alternative explanations for 
the reported concerns being identified.
The guidance takes account of alternative causes 
of the alerting features, both in the recommenda-
tions and the processes associated with considering 
and suspecting child maltreatment.
Overcoming barriers
Child maltreatment is a sensitive and emotive sub-
ject. Healthcare professionals face many obstacles 
to recognising and responding to possible maltreat-
ment (box). This guidance aims to empower and help 
them to overcome these obstacles, to encourage the 
appropriate course of action to protect the child or 
young person from further harm, and to reduce both 
delay in timely action and the high cost of abuse and 
neglect to individuals and to society.3 Support, super-
vision, education and training of ‘front line staff’ will 
be essential if this guidance is to be implemented suc-
cessfully. Improving the quality of recognition should 
result in the right child being referred to specialist 
services for further assessment and protection from 
further maltreatment.
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Obstacles for health professionals in identifying child 
maltreatment 
Concern about missing a disorder which is treatable•	
Discomfort of disbelieving, thinking ill of, suspecting, or •	
wrongly blaming a parent or carer 
Fear of losing a positive relationship with a family already •	
under the care of the health professionals
Divided duties towards adult and child patients and •	
breaching confidentiality
An understanding of the reasons why the maltreatment •	
might have occurred and a belief that the parent or carer 
did not intend to harm the child
Fear of loss of control over the child protection process •	
and doubts about the benefits
Stress•	
Personal safety•	
Fear of complaints•	
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RATIOnAl TEsTInG
Assessing candiduria in a critically ill patient
William W Hope
Candiduria is common and often benign, but it may be the only clue to disseminated 
candidiasis in critically ill patients
• Perineal contamination due to the use of broad 
spectrum antimicrobial agents;
• Colonisation of the lower urinary tract or the 
urinary catheter, facilitated by disruption of 
mechanical barriers by the indwelling catheter 
and changes in local bacterial flora by the use of 
broad spectrum antimicrobials;
• A marker of upper renal tract disease, which 
usually occurs in the context of structural urinary 
tract abnormalities or diabetes, and is sometimes 
complicated by the formation of fungal balls or 
bezoars8;
• A manifestation of disseminated infection; 
candiduria may be the only evidence of 
disseminated candidiasis in a critically ill patient.8
Unfortunately, no diagnostic tools distinguish these 
syndromes reliably.
Formal identification and testing for antifungal 
susceptibility 
For this critically ill patient with persistent intra-abdom-
inal infection refractory to broad spectrum antibacterial 
agents, disseminated candidiasis with seeding of the 
kidneys and “spill” into the urine is a strong possibility, 
and more information regarding the Candida isolate is 
required to guide treatment. Microbiology laboratories 
differ in the extent of the routine workup of a yeast iso-
lated from a non-sterile site, and formal identification 
and susceptibility testing may need to be requested 
specifically. A germ tube test is a relatively rapid way 
of distinguishing C albicans (germ tube positive) from 
other non-albicans species of Candida (for example, C 
parapsilosis, C glabrata, C tropicalis, and C krusei). This test 
consists of incubating the organism in sheep serum for 
two hours and checking whether blastoconidia, the initial 
outgrowths produced in fungal germination, are present. 
The high specificity of this test is marginally compro-
mised by C dubliniensis, which is also germ tube positive. 
Some germ tube negative organisms have reduced sus-
ceptibility to fluconazole (C glabrata, for example) or are 
inherently resistant (C krusei, for example) to this agent. 
For this patient with a potentially important germ tube 
negative yeast, formal identification and testing for anti-
fungal susceptibility are needed so that optimal antifun-
gal treatment can be administered. 
A heavy growth of Candida from urine is not nec-
essarily more likely to be clinically important (in con-
trast to bacterial growths), given the poor correlation 
between colony counts and disseminated infection.9 
Experimental models of disseminated candidiasis indi-
cate that  Candida casts in urine are a useful marker of 
School of Translational Medicine, 
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The patient
A 56 year old man was admitted to the intensive care 
unit from a general surgical ward with pancreatitis, diag-
nosed on the basis of clinical findings and a high amylase 
concentration thought to be secondary to alcohol abuse. 
He had no relevant medical history. In the general surgi-
cal ward he had been initially treated with ampicillin, 
gentamicin, and metronidazole to cover the likely bac-
terial pathogens. His early clinical course in intensive 
care was complicated by persistent fevers to 39.5°C, 
haemodynamic instability, acute renal failure, and adult 
respiratory distress syndrome. Mechanical ventilation 
was needed. A subclavian central line, arterial line, and 
indwelling catheter were required for supportive care. 
Computed tomography soon after admission to intensive 
care did not show any collection within the pancreas. 
On his admission to intensive care, antimicrobial treat-
ment was broadened to meropenem because of persist-
ent inflammation. Because of several risk factors for 
disseminated candidiasis (pancreatitis, broad spectrum 
antibacterial agents, and central venous catheterisation), 
intravenous fluconazole 400 mg daily was added on day 
3 in intensive care to cover Candida empirically.
The patient had persistent neutrophil leukocytosis, 
and blood cultures grew no organisms. On day 14 in 
intensive care, a catheter specimen of urine showed 
>500 white blood cells and 105 organisms/ml of a yeast 
that produced negative results on the germ tube test.
What is the next investigation?
The next laboratory investigation in this patient 
depends on the likely clinical importance of the 
candiduria. Candiduria is uncommon in otherwise 
healthy individuals but is found in 19-44% of criti-
cally ill patients,1-3 and the probability of candiduria 
increases progressively with the duration of the stay in 
the intensive care unit.1 In critically ill patients, candi-
duria may precede or be a marker of life threatening 
systemic infection; in a recent observational study of 
patients in intensive care from France, for example, 
about 8% of candiduric patients had candidaemia.4 
Because 40-50% of affected patients die from dissemi-
nated candidiasis,5 and in the absence of accurate tests 
for this condition, many doctors in intensive care have 
a low threshold for administering empirical systemic 
antifungal treatment.6 This results in many patients 
being treated unnecessarily. Moreover, although fluco-
nazole is effective for treating candiduria in the short 
term, the rate of relapse is high.7 
The diagnostic possibilities related to candiduria for 
this patient are:
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 disseminated  infection, but these are not routinely sought 
in the microbiology laboratory.10
Blood cultures
Blood cultures remain the diagnostic mainstay for the 
diagnosis of candidaemia, although their sensitivity is 
about 50%.11 To optimise yield from blood cultures, two 
or three blood samples must be drawn because the total 
volume of blood is an important determinant of overall 
sensitivity. Negative blood cultures do not exclude the 
possibility of disseminated candidiasis, and should not 
influence the use of systemic antifungal agents if such 
agents would be used on clinical grounds alone (as in 
this case).
Non-culture tests
Non-culture tests are not universally available at present 
but are likely to be used increasingly in the future.
• 1,3-β-D glucan is a soluble antigen found in some 
(but not all) medically important fungal genera, 
such as Candida and Aspergillus. In this patient, 
positive results on testing for glucan may support 
a diagnosis of disseminated candidiasis, although 
the specificity of this test may be suboptimal in 
patients in intensive care units12
• Polymerase chain reaction on blood to detect 
Candida may provide evidence of disseminated 
infection, but this is not widely used because 
assays have not been standardised
• Testing for combined Candida mannan antigen 
and antibody is potentially useful,13 but not all 
species of Candida contain mannan, and these 
tests require considerable laboratory resources.
other microbiological data
The presence of Candida at multiple non-sterile sites 
is a risk factor for disseminated candidiasis, and some 
clinicians use this as a trigger for empirical  antifungal 
treatment. Routine surveillance cultures for Candida at 
non-sterile sites to guide antifungal therapy is  relatively 
expensive and time consuming and is not widely 
 practised.
Outcome
There was no evidence of pyelonephritis on ultrasonog-
raphy. The indwelling catheter was changed. The germ 
tube negative yeast was identified as C glabrata with a 
minimal inhibitory concentration of 32 mg/l, suggesting 
reduced susceptibility to fluconazole (the precise designa-
tion is susceptible dose dependent, indicating a higher 
fluconazole dosage is needed for successful treatment). 
Probable disseminated C glabrata candidaemia with 
“spill” into the urine was diagnosed. Increasing flucona-
zole from 400 mg/day to 800 mg/day was inappropriate 
because the infection had arisen despite fluconazole. His 
renal impairment provided a relative contraindication 
to the administration of liposomal amphotericin B, so 
treatment was changed to caspofungin, an echinocandin, 
which was given as a 70 mg loading dose followed by 
a maintenance dose of 50 mg/day. The echinocandins 
are broad spectrum antifungal agents with rapid candi-
dacidal activity that can be safely used in patients with 
renal and hepatic impairment. Computed tomography 
on day 19, carried out because of slow clinical progress, 
showed a small collection of fluid in the pancreas. A 
percutaneous aspirate also grew C glabrata with the same 
minimal inhibitory concentration. Signs of sepsis slowly 
resolved with echinocandin treatment, and the patient 
was eventually discharged from intensive care. The use 
of a relatively simple microbiological test for formal iden-
tification and testing of antifungal susceptibility on a uri-
nary isolate enabled timely and appropriate antifungal 
treatment to be administered. 
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lEARnInG POInTs
Distinguishing the causes of candiduria (perineal contamination, colonisation of the lower •	
urinary tract, upper tract infection, and “spill” into the urine from blood borne Candida 
infection) requires a compilation of clinical, microbiological, and radiological data
Though candiduria is most often of little clinical consequence and does not need treating, •	
in some clinical contexts such as critically ill patients, it may be the only manifestation 
of life threatening disseminated Candida infection, which needs aggressive systemic 
antifungal treatment
Asymptomatic candiduria in clinical contexts where disseminated infection is unlikely •	
does not usually require treatment. A change of  indwelling catheter  may be appropriate
Fluconazole is the agent of choice for infection confined to the renal tract because of its •	
water solubility and high urinary concentrations
When candiduria is a manifestation of disseminated infection, treatment should be •	
directed to the primary site(s) of infection, and a triazole, echinocandin, or a lipid 
preparation of amphotericin B are the agents of choice
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lEssOn Of ThE WEEK
A case of mistaken mesial temporal identity
A Neligan,1 D R Holdright,2 F J Rugg-Gunn,1 J W Sander1
Re-examine a diagnosis of epilepsy when there is worsening control and investigations 
are normal
 profound sleep with heavy snoring. He recovered about 
30 minutes later, initially shouting as if waking from a 
bad dream, but without subsequent confusion. There 
was neither urinary incontinence nor tongue biting. He 
was seen by a neurologist who felt these episodes were 
epileptic in origin; no treatment was recommended as 
the episodes had been infrequent. He had a further epi-
sode five days later and was seen by a second neurologist 
who made a putative diagnosis of mesial temporal lobe 
epilepsy and prescribed carbamazepine 200 mg twice 
daily. These now stereotyped episodes continued to 
occur increasingly frequently, despite an escalating regi-
men of anti-epileptic medications. He would perceive 
a sweaty smell and feel a severe constricting left-sided 
chest pain, sometimes radiated to the jaw, associated with 
profuse sweating. He was uncomfortable, would try to sit 
down, and would breathe heavily. A few seconds later 
he might lose consciousness for up to 30 minutes, snore 
loudly and shout on waking. Episodes of chest pain with-
out loss of consciousness were interpreted as complex 
partial seizures, and the episodes with loss of conscious-
ness were interpreted as partial seizures with secondary 
generalisation. An MRI brain scan and routine electro-
encephalogram were reported as normal.
At this stage he was taking sodium valproate 2000 
mg, carbamazepine 600 mg, lamotrigine 150 mg, and 
clobazam 30 mg daily. Despite this, the partial seizures 
continued on an almost daily basis, and the generalised 
episodes recurred at least every seven days. When first 
seen, the patient was feeling lethargic and drowsy. On 
direct questioning he reported no history of myoclonic 
jerks, events  suggestive of complex partial seizures, or 
convulsive episodes. There were no clear triggers for 
the episodes, and all occurred early in the morning or 
during the night. He subsequently underwent a further 
MRI brain scan, which was normal, and a 24 hour elec-
troencephalogram, which was mildly encephalopathic in 
keeping with his medication. It was felt that the diagnosis 
of epilepsy was unlikely and that these episodes were 
cardiac in origin, despite normal cardiac investigations. 
The patient underwent a MRI scan of his cervical spine 
looking for a possible cervical disc herniation, which can 
atypically present as ischaemic chest pain.1 
The scans were normal. The patient was referred 
to a cardiologist for further evaluation, and the anti-
epileptic medication was slowly withdrawn, resulting 
in a substantial improvement in his cognition. After 
cardiological assessment, including an echocardio-
gram that showed no evidence of structural heart 
disease, and a 12 lead electrocardiogram that was 
normal (fig 1), he had an implantable loop recorder 
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and Neurosurgery, London  
WC1N 3BG
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fig 1 | Twelve lead electrocardiogram done at initial cardiology assessment showing normal 
sinus rhythm
The accurate diagnosis and treatment of paroxysmal 
events can be difficult. It requires a detailed eye witness 
account and a clear description of the circumstances of 
the event, including location, development, tempo, and 
duration. Even with this information, a definitive diag-
nosis may not be attainable.
Case report
A 45 year old left handed man presented with a four year 
history of paroxysmal events. He was referred by his 
neurologist for consideration of epilepsy surgery. Previ-
ous medical history was unremarkable. The first episode 
of loss of consciousness occurred while the patient was 
with friends. It was preceded by a brief period of severe 
chest pain with profuse sweating, which lasted less than 
a minute. A 12-lead electrocardiogram was normal. The 
second episode occurred two years ago and was also pre-
ceded by chest pain. During this episode, the patient felt 
weak, lay on the ground, and lost consciousness. Dura-
tion was uncertain, but on regaining consciousness he 
was sweating profusely. He interpreted these episodes 
as cardiac in origin as he has a strong family history of 
coronary artery disease. He was seen by a cardiologist 
who noted a normal cardiac examination, ambulatory 
electrocardiogram, exercise stress test, and transthoracic 
echocardiogram.
He had no further episodes until about nine months 
before referral. The first new episode started with a sen-
sation of a sweaty smell followed by constricting chest 
pain for approximately 30 minutes, after which he lost 
consciousness. His wife described him as being in a 
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(Reveal) inserted. Six days later, he had an episode, 
and the Reveal electrocardiogram tracing showed the 
development of ventricular tachycardia, degenerating 
over a three minute period to ventricular fibrillation, 
with spontaneous termination and resumption of sinus 
rhythm (fig 2).
Coronary angiography revealed only early non-
obstructive plaque disease throughout the left coro-
nary artery. During the angiogram, severe coronary 
artery spasm developed in the atrioventricular cir-
cumflex, which responded fully to intracoronary 
nitrates. The device was removed, and a dual-chamber 
implantable cardioverter-defibrillator was implanted. 
A cardiac MRI scan was not performed prior to the 
insertion of an implantable cardioverter-defibrillator 
as it was believed that it would be unlikely to alter 
management. He was started on sotalol, a β blocker 
with anti-arrhythmic properties, and diltiazem, a cal-
cium channel antagonist, to prevent coronary artery 
vasospasm.
At last follow-up six months later he was well and 
asymptomatic off all anti-epileptic medication.
discussion
The differential diagnosis of paroxysmal events is exten-
sive and often summarised as “fits, faints, and funny 
turns.” The diagnosis of epilepsy is clinical, based mainly 
on the eye witness account, although this may be mis-
leading.2 About 20% of patients attending a seizure clinic 
with refractory epilepsy do not have epilepsy.3 In this 
case, the sensation of a smell at the start of each episode, 
the termination of the attack with a loud shout, and the 
prolonged duration of some of the episodes suggest a 
diagnosis of complex partial seizures with secondary 
generalisation, possibly arising from the temporal lobe. 
Some patients report a distinct and identifiable smell 
during an epileptic seizure, but they are often unable to 
identify it clearly. In this case, an unambiguous smell of 
sweat suggests the presence of autonomic disturbance 
associated with a primary cardiac problem and not an 
epileptic olfactory aura. Additional characteristics of the 
attack, such as profuse sweating and chest pain, suggest 
an alternative diagnosis. Chest or abdominal discomfort, 
however, can occur in partial seizures with associated 
autonomic dysfunction, leading to diagnostic uncertainty. 
The severity and quality of the chest discomfort seem 
disproportionate in this case to that expected for a par-
tial seizure with associated visceral pain and autonomic 
features.
While a cardiac diagnosis appears much more likely 
with the benefit of hindsight, there may have been subtle 
differences in the history elicited by the primary neuro-
logical team that were more indicative of episodes of 
epileptic aetiology. The main differential diagnoses of 
epilepsy are primary cardiac events, neurocardiogenic 
(vasovagal) syncope, and psychogenic non-epileptic 
attacks. In one study, conducted at a tertiary epilepsy 
unit, 26% of patients attending for refractory epilepsy 
were found to have an alternative diagnosis4 (including 
syncope and psychogenic attacks), and another study 
by a cardiology service found 42% of those with appar-
ent refractory epilepsy had an alternative, cardiological, 
diagnosis.5 Gastaut estimated that up to a third of patients 
who were given an initial diagnosis of epileptic seizures 
had an underlying cardiovascular condition.6 In particu-
lar, cardiac arrhythmias can masquerade as seizures and 
were found to be the cause of collapse in 20% of patients 
in one study.7
Transient cardiac asystole can present as intractable 
epilepsy8 and may occur in association with epileptic 
seizures, leading to diagnostic difficulties.9-11 Cardiac 
syncope, secondary to structural cardiac abnormality, 
ischaemia, or arrhythmia, has an overall mortality of 30% 
at five years12 and can be difficult to confirm if the resting 
12 lead electrocardiogram is normal.13 An exception to 
this is the long QT syndrome, which can present with 
episodes of sudden collapse,14 15 but importantly the rest-
ing electrocardiogram is usually abnormal, although this 
can vary over time. The yield from 24 hour ambulatory 
electrocardiogram monitoring in patients with infrequent 
episodes of collapse is typically poor.16 The implantable 
loop recorder is of tremendous diagnostic value, with a 
high yield in this patient group.17
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10-MInuTE COnsulTATIOn
Acne vulgaris
Fiona Hamilton,1 Josip Car,1 Alison Layton2 3
A 17 year old woman comes to see you with a 12 month 
history of pimples and pustules on her face, with a few 
blackheads and no scarring. She says they are making 
her feel very self conscious and are affecting her A level 
studies and social life.
What issues you should cover
• What other symptoms or signs does she have? 
Seborrhoea, irregular menses, weight gain, or 
hirsutism should alert you to polycystic ovary 
syndrome. 
• Is she worried that her diet is causing her acne? 
Currently no conclusive evidence exists to 
confirm that foods such as chocolate contribute 
to acne, so it is a good opportunity to dispel 
myths and to discuss healthy eating in general.
• Does she have any particular skin care regime? 
Often people with acne use aggressive cleaning 
products, which can aggravate the problem or 
cause irritation.
• Is she taking any prescribed or over the counter 
treatments? Some treatments, particularly 
antiepilepsy drugs, steroid creams, anabolic 
steroids, and some hormonal treatments, can 
cause or worsen acne.
• Would she consider hormonal treatment for 
acne? This would also give you the opportunity 
to discuss her sexual health, if appropriate.
• How does the acne affect her mood and social 
life? Acne can lead to low self-esteem and 
depression, so you could ask her how it affects 
her mood and whether it stops her doing 
anything she would normally enjoy doing.
What you should do
• Assess and record the severity of the acne so that 
the effects of treatment can be compared with 
your baseline evaluation. There is no standard 
acne grading system, but the Leeds revised acne 
scoring system uses several useful photographs 
(see Further reading). A pragmatic approach is 
to record the acne as mild, moderate, or severe 
(table).
• Explain to her that acne is a very common 
but treatable skin condition and is caused by 
inflammation of the oil glands around hair 
follicles, usually triggered by the hormones 
of puberty. Point her to a website for more 
information (see Further reading).
• Advise her to use a mild cleanser, an oil free 
moisturiser, and non-comedogenic make-up, if 
she wears any; to avoid touching her face; and 
not to pick the spots, which can worsen acne and 
lead to scarring.
• Although the evidence for an association 
between acne and smoking or alcohol misuse 
conflicts, take the opportunity to give her 
general advice on health promotion about these 
habits where necessary.
• Arrange further investigations for polycystic 
ovarian syndrome if indicated, such as blood 
tests for endocrine hormone alterations or 
ultrasonography of the ovaries (see Further 
reading for advice on referral).
• Advise her that early treatment prevents 
scarring and that any treatment needs to 
be tried for at least six weeks before its 
effectiveness can be assessed.
This is part of a series of 
occasional articles on common 
problems in primary care. The 
BMJ welcomes contributions 
from GPs
Grading of acne severity and treatment
Mild acne Moderate acne Severe acne
Description Open and closed 
comedones 
(whiteheads and 
blackheads), a few 
papules and pustules
Comedones, more frequent 
papules and pustules, but 
minimal scarring; can be 
subdivided into mainly 
comedonal or mainly 
inflammatory acne
Comedones, more 
pustules, and pustules 
plus nodular abscesses 
with more extensive 
scarring
First line treatments •	Topical	retinoid 
•	Benzoyl	peroxide	(BP) 
•	BP	+	topical	antibiotic
Comedonal:  
•	BP	+	topical	retinoid
Inflammatory:  
•	BP	+	topical	antibiotic
As for moderate acne, plus 
referral to a dermatologist 
for oral isotretinoin
Second line 
treatments
•	Azelaic	acid •	Oral	antibiotic	+	BP	±	topical	
retinoid 
•	Azelaic	acid 
•	Consider	combined	oral	
contraceptive pill for female 
patients
As for moderate acne, plus 
referral to a dermatologist 
for oral isotretinoin
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First line treatments
• Topical retinoids, the first line treatment for 
mild acne, have comedolytic, anti-comedogenic, 
and anti-inflammatory effects and are good in 
early and established acne and as maintenance 
therapy. The most common side effects are 
dryness and irritation, which can be avoided by 
application on alternate days initially. In theory 
retinoids are teratogenic, so women should be 
advised about this.
• An alternative to topical retinoids is 
benzoyl peroxide. It is highly effective at 
reducing antibiotic sensitive and resistant 
propionibacterium acnes so is good for 
inflammatory acne and is more effective than 
topical antibiotics. It has mild comedolytic 
activity but no anti-comedogenic action. It can 
cause dryness and irritation, so start with a 
low strength cream formulation and titrate up. 
Advise that it can bleach clothes.
• Topical antibiotics are also helpful in mild to 
moderate inflammatory acne but should be used as 
combination formulations with benzoyl peroxide 
to help reduce the risk of bacterial resistance.
Second line treatments
• Topical azelaic acid 20% works in a similar way 
to benzoyl peroxide and retinoids but is less 
irritating. It is likely to be much less effective than 
retinoids and benzoyl peroxide but is helpful in 
patients with post-inflammatory pigmentation.
• For moderate acne a generic tetracycline 
(but not minocycline, because of the risk of 
skin pigmentation and other more serious 
adverse effects) is recommended for at 
least six weeks, in combination with topical 
treatment. Combining an oral antibiotic with 
benzoyl peroxide helps to reduce the risk of 
bacterial resistance. Advise female patients that 
tetracyclines are contraindicated in pregnancy 
and that they should take adequate measures 
to avoid conceiving. Tetracyclines should not 
be prescribed to children aged under 12 years, 
because of potential staining of teeth enamel.
• Hormonal treatment may improve acne in 
some women. There is little evidence that 
any is better than the others. Given the 
potential for adverse effects, particularly 
venous thromboembolism (VTE), you should 
consider the risk-benefit ratio when prescribing 
hormonal treatment. Any hormonal treatment 
is contraindicated in women with focal 
migraine or a higher than normal risk of VTE. 
Co-cyprindiol has a product licence for severe 
acne and can improve acne in up to 90% of 
female patients. Because of concerns about the 
risk of VTE, the advice is that this be given for 
3-4 cycles after the acne is completely resolved 
then withdrawn (repeat courses may be given 
for recurrence). However, a recent paper by 
S Franks and colleagues (see Further reading) 
has shown that this is not necessary, as there 
is no good evidence to confirm an increased 
VTE risk, and there are moves to change this 
recommendation.
• Consider referral if the above described 
treatments do not result in the desired outcomes 
(see box).
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Guidance on referral to a specialist  
(based on NICE guidance, May 2001)
Consider referral if the patient has:
Severe acne or painful nodulo-cystic acne, with •	
potential or actual scarring. Such acne is likely to benefit 
from isotretinoin, an oral retinoid that is very effective 
but can have serious side effects, ranging from dry skin, 
lips, and eyes to teratogenicity and possible mood 
changes. It can be prescribed only by a dermatologist
Severe social or psychological problems as a result of •	
the acne
Moderate acne after six months of trying treatment in •	
primary care, or
A suspected underlying endocrine cause, such as •	
polycystic ovary syndrome.
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